21. Arch Pediatr Adolesc Med -- Abstract: Primary Ovarian Failure, Juvenile Rheumato primary ovarian failure, juvenile rheumatoid arthritis, and vitiligo. RJ Collen, BM Lippe and SA Kaplan. A female adolescent with primary ovarian failure http://archpedi.ama-assn.org/cgi/content/abstract/133/6/598

Select Journal or Resource JAMA Archives of Dermatology Facial Plastic Surgery Family Medicine (1992-2000) General Psychiatry Internal Medicine Neurology Ophthalmology Surgery Student JAMA (1998-2004) JAMA CareerNet For The Media Meetings Peer Review Congress Vol. 133 No. 6, June 1979 Featured Link E-mail Alerts ARTICLE Article Options Send to a Friend Readers Reply Submit a reply Similar articles in this journal Literature Track Add to File Drawer Download to Citation Manager Articles in PubMed by Collen RJ Kaplan SA Articles that cite this article Contact me when this article is cited Primary ovarian failure, juvenile rheumatoid arthritis, and vitiligo R. J. Collen, B. M. Lippe and S. A. Kaplan A female adolescent with primary ovarian failure was found to have circulating autoantibodies to her ovaries. Primary ovarian failure in pediatrics is usually attributed to gonadal dysgenesis. Autoimmune oophoritis is a rare cause and is most often associated with Addison's disease and other autoimmune endocrinopathies. Our patient also had juvenile rheumatoid arthritis and vitiligo. To our knowledge, this case

22. Entrez PubMed Sixteen Korean female laborers who had been exposed to a cleaning solvent composed mainly of 2bromo http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9

23. Entrez PubMed Eightyone patients who had a diagnosis of primary ovarian failure were studied to determine its pos http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6

24. Obstetrical & Gynecological Survey - UserLogin and the Delay of Pubarche Indicate primary ovarian failure in Turner Syndrome in 22 of these girls, whereas 45 had primary ovarian failure (POF). http://www.obgynsurvey.com/pt/re/obgynsurv/fulltext.00006254-200412000-00011.htm

LWWOnline LOGIN eALERTS REGISTER ... Archive You are attempting to access protected content. To access this content please login using an established account or create/activate an account. If you have already created/ activated an online account, please login below: User Name: Password: Note: passwords are CASE SENSITIVE If you are a new user or guest visiting an LWWonline site for the first time, please complete the new account setup process to view or purchase content. Forgot your password? Subscribe Renewal Information Subscribe to RSS feed utrdc-pt02 Release 4.0

25. Obstetrical & Gynecological Survey - Abstract: Volume 59(12) December 2004 P 824 and the Delay of Pubarche Indicate primary ovarian failure in Turner Syndrome. in 22 of these girls, whereas 45 had primary ovarian failure (POF). http://www.obgynsurvey.com/pt/re/obgynsurv/abstract.00006254-200412000-00011.htm

LWWOnline LOGIN eALERTS REGISTER ... Archive The Early Dehydroepiandrosterone... ARTICLE LINKS: Fulltext PDF (258 K) Permissions The Early Dehydroepiandrosterone Sulfate Rise of Adrenarche and the Delay of Pubarche Indicate Primary Ovarian Failure in Turner Syndrome. Martin, David D.; Schweizer, Roland; Schwarze, C Philipp; Elmlinger, Martin W.; Ranke, Michael B.; Binder, Gerhard Abstract: Girls with Turner syndrome provide the first human model in which adrenal puberty (adrenarche) takes place without gonadal puberty. A wide range of serum dehydroepiandrosterone sulfate (DHEAS) concentrations has been observed, ranging from normal to very elevated. This study attempted to determine whether the course of adrenarche and pubarche is independent of ovarian function. A total of 867 serum DHEAS estimates were made over time in 111 girls with Turner syndrome. Puberty began spontaneously in 22 of these girls, whereas 45 had primary ovarian failure (POF). Serum DHEAS levels were compared with those of 322 healthy girls 3 to 17 years of age. POF was defined as a lack of spontaneous breast development and at least 1 follicle-stimulating hormone (FSH) level of 50 IU/L or higher before estrogen replacement therapy. Age-related serum concentrations of DHEAS were significantly higher in girls with Turner syndrome than in control girls from ages 7 to 17 years. Those with POF had significantly higher age-related levels than did girls experiencing spontaneous puberty at ages 9 to 15 years. Adrenarche occurred at a median age of 8.3 years in girls with POF, compared with 10.5 years for girls with spontaneous puberty and 11 years in normal girls. In both groups with Turner syndrome, mean DHEAS levels correlated closely with mean FSH and luteinizing hormone levels. Pubarche was delayed in girls with POF despite their high serum DHEAS levels. Puberty occurred more than 4.5 years after adrenarche, at a median age of 13 years, in girls with Turner syndrome, whereas in girls with spontaneous puberty, the interval was 1.4 years and the median age at pubarche was 11.9 years.

26. Estrogen Therapy Patch Comparison - VivelleDot.com hypoestrogenism due to hypogonadism, castration, or primary ovarian failure; and for the prevention of postmenopausal osteoporosis (loss of bone mass). http://www.vivelledot.com/eng_pro/patch_comparison.cfm

Vivelle-Dot estrogen therapy sitemap menopause symptoms hot flashes ... Site Map It's the Tiny Patch Home Healthcare Professionals It's the Tiny Patch Here are some photos of Estrogen Therapy (ET) patches. Take a look and see for yourself that Vivelle-Dot is the smallest Estrogen Therapy (ET) patch available. Please note that differences in patch size do not imply differences in safety or efficacy. Please note measurements for both Estraderm and Mylan Estradiol Transdermal System reflect active surface area only, not total surface area. Estraderm (estradiol transdermal system) is indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; atrophic vaginitis and kraurosis vulvae, atrophic urethritis, hypoestrogenism due to hypogonadism, castration, or primary ovarian failure; and for the prevention of postmenopausal osteoporosis (loss of bone mass). (estradiol transdermal system) is indicated for the treatment of moderate-to-severe vasomotor symptoms assocated with menopause; vulval and vaginal atrophy, and hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.

27. Jansen - Low Thyroid Function And An Elevated Day 3 FSH. What Does It Mean? But neither thyroid disease nor primary ovarian failure is rare. In practice, the association is often a coincidence. These are the relevant facts. http://www.jansen.com.au/Answer4.html

Robert Jansen MD Very interesting questions. Updated Jan 2004. Low thyroid function and an elevated day 3 FSH. What does it mean? Q . Your discussion of Autoimmune Oophoritis (in Overcoming Infertility) piqued my interest because I was just diagnosed with slight hypothyroidism for which I am taking Synthroid. I will be undergoing new day 3 FSH levels in a couple of weeks after having been on the medication for the last month, in the hope that my FSH levels are back to normal or at least below 10. I do not have painful enlargement of the ovaries, but I gather that autoimmune oophoritis might not show up as the painful enlargement of the ovaries until all the follicles have been burned out. You say that tissue antibodies such as thyroid antibodies are looked for, however they are rarely present. What I can't figure out is, if thyroid antibodies are present (like with me) and the ovaries aren't enlarged, and the thyroid problem is corrected, what happens? Can some good follicles be left? If so, if FSH levels start looking good again is there some hope? There are real connections between an underactive thyroid and problems with ovulation. But neither thyroid disease nor primary ovarian failure is rare. In practice, the association is often a coincidence.

28. Overcoming Infertility primary ovarian failure. Failure of the ovaries to produce enough follicles, because of a problem in the ovary itself, and resulting in depletion of eggs http://www.jansen.com.au/silver/glossary.asp?keyword=primary ovarian failure

29. The Survival Guide To Obstetrics & Gynaecology Pathological primary ovarian failure secondary ovarian failure polycystic ovarian syndrome systemic endocrine disorder anatomical http://www.fleshandbones.com/guides/obgyn.cfm

Log in Register now You are here: Home Survival Guides Author: Nicola Campbell What's it all about? Conditions you will be asked about in your first week Abnormal vaginal bleeding Pre-eclampsia Do's and don'ts History and Examination Printer-friendly version (requires Adobe Acrobat) What's it all about? The doctor is usually both an obstetrician and a gynaecologist, although some have special interests and some sub-specialise further. There are overlaps between the two subjects, but essentially obstetrics is the science of pregnancy, and gynaecology is female reproductive medicine. In the course of obstetrics and gynaecology, you might also cover sexual health more widely, areas such as male reproductive health and infertility. The practice of obstetrics and gynaecology includes outpatient clinics, inpatients, theatre, assisting with deliveries and possibly some postnatal and neonatal care. Conditions you will be asked about in your first week Abnormal vaginal bleeding In considering abnormal vaginal bleeding here, we will not cover bleeding during diagnosed pregnancy. Definitions Primary amenorrhoea Failure to start menstruating (by 16 years) Secondary amenorrhoea Lack of menstruation for >6 months (not due to pregnancy) Oligomenorrhoea Infrequent periods, >42-day cycle

30. ANZJM Vol. 30 No. 1 February 2000 - Editorials The prevalence of autoimmune disorders among patients with primary ovarian failure. Familial idiopathic premature ovarian failure an overrated and http://www.racp.edu.au/anzjm/fe00ed3.htm

Vol. 30 No. 1 February 2000 Editorials X chromosome defects and premature ovarian failure Communications to: Research Centre in Reproductive Medicine, Department of Obstetrics and Gynaecology, National Women's Hospital, Auckland, New Zealand. Email: a.shelling@auckland.ac.nz Two articles in this issue of the Journal by Driscoll et al. ) and McAuley et al ) describe patients with premature ovarian failure (POF) with associated defects on the X chromosome which offer insights into the aetiology of this complex disorder. POF is characterised by secondary amenorrhoea, hypoestrogenism, and elevated gonadotrophins in women under the age of 40 years. It is a common condition and occurs in 1% of women under the age of 40 years, and will affect 0.1% of women before the age of 30 years.( ) POF is becoming a challenging issue for couples, particularly as women delay having families until later in life. Two significant consequences of POF are the loss of fertility, and the clinical effects of hypoestrogenism. Low levels of oestrogen from a young age appear to increase the risk of osteoporosis and coronary heart disease.( POF is clearly a heterogeneous disorder, and only a few causes can be identified.(

31. Cancer Chemotherapy And Fertility is the major cause of amenorrhea, which is due to primary ovarian failure. In ovarian failure or menopause, the ovary is depleted of all follicles, http://www.cancernews.com/articles/cancer&fertility.htm

This article is provided for information purposes only. It is not intended to be used for medical advice. Please read Used by the permission of The Patient Resource Center Salick Health Care, Inc. Cancer News on the Net Breast Cancer in Young Women : Effect of Chemotherapy on Ovarian Function, Fertility, and Birth Defects Bonnie S. Reichman, Karen B. Green A comprehensive review of the literature was done to assess the effect of adjuvant chemotherapy for operable breast cancer on ovarian function, fertility, and birth defects. Data were limited. Cyclophosphamide, an alkylating agent, is the major cause of amenorrhea, which is due to primary ovarian failure. Ovarian dysfunction is related to age, dose, and duration of treatment. In women less than 35, pregnancy following adjuvant chemotherapy is possible. However, data are limited regarding the impact of subsequent pregnancy on the results of breast cancer. There appears to be no increased risk of teratogenesis in offspring exposed to chemotherapy after the first trimester of pregnancy. Prospective data on women who have subsequent pregnancies and their offspring are very limited. Formation of a registry for long-term follow-up of young women detailing reproductive potential and follow-up of offspring is needed. [Monogr Natl Cancer Inst 16:125-129, 1994] A single dominant follicle is selected by days 5-7 in the ovarian menstrual cycle, with ovulation of a fertilizable egg at day 14. All other follicles that were recruited in that cycle undergo atresia. As the dominant follicle emerges, there is increasing production of estrogen that stimulates the mid-cycle luteinizing hormone (LH) and follicle-stimulating hormone (FSH) surge. The abrupt rise in LH leads to meiotic maturation of the oocyte before ovulation, release of the oocyte by the ovulating process, and formation of the corpus luteum by luteinization of the granulosa and theca cells of the dominant follicle.

32. Faces Of POF: Preview Faces of POF Living and Learning with Premature Ovarian Failure. I was diagnosed with primary ovarian failure at age sixteen. http://www.pofsupport.org/facesofpof/preview.htm

Faces of POF Preview: Marrianne Followed from Living with POF Marrianne, forty-three, diagnosed at sixteen I was diagnosed with primary ovarian failure at age sixteen. I have lived with this diagnosis and have been on hormone replacement therapy for twenty-five years. I hope that my story might help others who have been diagnosed with this rare form of premature ovarian failure. I grew up as many girls did, looking forward to the time when I would be a mother to my own children. I would pretend to be pregnant with a pillow or dolly under my shirt. I also grew up in an atmosphere where marrying, being a mother, and raising children was a large part of who I would be. This was reinforced by my religious community. My parents raised me as early as age six with information about where babies came from and how they developed in a woman. As I grew older I learned about my body maturation. In seventh grade, I looked forward to the day I would have my first period along with my friends. Not working on having a child is still new to me. I still get twinges of disappointment and discomfort when I see other pregnant women, or when I see mothers holding their infants. I have felt less lonely in my situation as I have visited the POF support board on the Internet. I appreciate the opportunity of connection, learning, and helping others more like myself. I am learning to add a little bit more of what I love doing, still giving and sharing with others to fill my life. I have many questions to ask God when I leave this world. Until then, I choose to keep going and doing the best I can.

33. The Society For Endocrinology - Training to damage by chemotherapy or radiation, or to autoimmune disease. The main genetic disease causing primary ovarian failure is Turner syndrome (45XO). http://www.endocrinology.org/sfe/training/ent00/ent00_dav.htm

Contents Home About Journals ... Links Society for Endocrinology Effects of Endocrine Dysfunction on Fertility J R E Davis Manchester Royal Infirmary, Manchester, UK Endocrine Nurses Training Course 4-6 September 2000 St Annes's College, Oxford, UK Hyperprolactinaemia Pituitary disease and hypothalamic disease each affect the normal patterns of production of gonadotrophins. Hyperprolactinaemia is the single commonest pituitary abnormality, and can result from pituitary adenomas, disruption of the pituitary stalk, and dopamine antagonist drugs, including phenothiazines, metoclopramide and domperidone. The effect of hyperprolactinaemia on women is most obvious because of abnormal lactation, but in both men and women excess prolactin suppresses the normal pulsatile release of GnRH from the hypothalamus and the gonadotrophins LH and FSH from the pituitary. The result in women is loss of the ovarian cyclical production of both mature oocytes and oestrogen, and in men, suppression of testosterone secretion and oligospermia, with loss of libido in both sexes. Structural causes of hypopituitarism Most other types of pituitary disease readily affect gonadotrophin production. Any destructive lesions of the pituitary or hypothalamus interfere with the normal pulsatile production of LH and FSH, and even if hormone levels remain within the reference range for a single sample, it is the disrupted pattern of secretion that is critical, resulting in a complete lack of gonadal response. Pituitary tumours, including Cushing's disease, acromegaly and non-functioning adenomas, may all have this effect, depending on the size and location of the tumour. Pituitary surgery, even selective microadenomectomy, carries a risk of damaging gonadotroph function, and radiotherapy ultimately causes progressive pituitary and hypothalamic damage resulting in gonadal dysfunction.

34. Eye & Contact Lens: Science And Clinical Practice - UserLogin primary ovarian failure, multiple thrombotic cerebrovascular accidents, Ovarian failure was documented through an endocrine workup that showed http://www.claojournal.org/pt/re/eclens/fulltext.00140068-200310000-00018.htm

LWWOnline LOGIN eALERTS REGISTER ... Archive You are attempting to access protected content. To access this content please login using an established account or create/activate an account. If you have already created/ activated an online account, please login below: User Name: Password: Note: passwords are CASE SENSITIVE If you are a new user or guest visiting an LWWonline site for the first time, please complete the new account setup process to view or purchase content. Forgot your password? Subscribe Renewal Information Subscribe to RSS feed utrdc-pt01 Release 4.0

35. Ovarian Failure After Adjuvant Chemotherapy Is Associated With Rapid Bone Loss I Chemotherapyinduced ovarian failure was defined as a negative pregnancy test, is primary ovarian failure.3-5 Permanent chemotherapy-induced ovarian http://www.jco.org/cgi/content/full/19/14/3306

Search for: Limit by: All Topics Original Reports Review Articles Special Articles Biology of Neoplasia Editorials Comments and Controversies Diagnosis in Oncology Art of Oncology Correspondence All Years Browse by Topic or Issue Home Search/Browse Subscriptions ... Customer Service This Article Abstract Full Text (PDF) Alert me when this article is cited ... Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Cited by other online articles PubMed PubMed Citation Articles by Shapiro, C. L. Articles by Leboff, M. Journal of Clinical Oncology , Vol 19, Issue 14 (July), 2001: 3306-3311 American Society for Clinical Oncology Ovarian Failure After Adjuvant Chemotherapy Is Associated With Rapid Bone Loss in Women With Early-Stage Breast Cancer By Charles L. Shapiro Judith Manola Meryl Leboff Address reprint requests to Charles L. Shapiro, MD, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University, Starling-Loving Hall B421, 320 West 10th Ave, Columbus, OH 43210; email: ABSTRACT TOP ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION REFERENCES PURPOSE: We sought to evaluate the effects of chemotherapy-induced ovarian failure on bone loss and markers of skeletal turnover in a prospective longitudinal study of young women with breast cancer receiving adjuvant chemotherapy.

36. 060101 - Bone Density Studies Other ovarian failure (ovarian hypofunction, primary ovarian failure). 259.3. Ectopic hormone secretion, not elsewhere specified http://www.empireblue.com/medical_policies_short/radiology/bone_density_studies.

CLINICAL Bone Density Studies Effective Date: 04/25/03 Revision Date: 04/25/03 Section: Radiology Subsection: Radiology Definition Policy Medical Appropriateness References ... Diagnosis Limitations Definition Bone mineral density (BMD) measurement is a non-invasive technique that is used to measure bone mineral content and bone mineral density. Its primary role is to detect osteoporosis and to predict the risk of fractures. There are several techniques, which are currently used to measure bone mass. These include single- and dual- absorptiometry, quantitative computed tomography, and ultrasonography. At the present time, dual energy (DEXA) is the most common employed method. While there are numerous independent risk factors associated with the development of primary osteoporosis, nearly one-third to one-half of all post-menopausal women are affected. Therefore, age and sex must be considered the most compelling risk factors. Routine screening in otherwise healthy patients is not of benefit in detection and treatment of osteoporosis. Bone mineral density is widely used to guide initiation of treatment of osteoporosis, and to monitor response to therapy. Because of the slow changes in bone mineral density and the precision of measuring technologies, specifically DEXA, monitoring response to therapy prior to two years is unlikely to detect changes. In addition, changes in bone mineral density at central sites (i.e. hip and spine) are often not reflected by changes in bone mineral density at peripheral sites. However, quantitative ultrasound is useful for assessing risk but not for diagnosing and monitoring of patients. Peripheral or central bone density tests are covered.

37. Endotext.com - Female Reproductive Endocrinology, Ch 2 Bibliography Aittomaki, K., et al., Clinical features of primary ovarian failure caused by a point mutation in the folliclestimulating hormone receptor gene. http://www.endotext.org/female/female2/femalebiblio2.htm

1. Tanner, J.M. and R.H. Whitehouse, Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child, 1976. 51(3): p. 170-9. 2. Marshall, W.A. and J.M. Tanner, Variations in pattern of pubertal changes in girls. Arch Dis Child, 1969. 44(235): p. 291-303. 3. Herman-Giddens, M.E., et al., Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics, 1997. 99(4): p. 505-12. 4. Kosho, T., et al., Skeletal features and growth patterns in 14 patients with haploinsufficiency of SHOX: implications for the development of Turner syndrome. J Clin Endocrinol Metab, 1999. 84(12): p. 4613-21. 5. Rao, E., et al., Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet, 1997. 16(1): p. 54-63. 6. Clement-Jones, M., et al., The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet, 2000. 9(5): p. 695-702. 7. Lee, M., Growth hormone deficiency as the only identifiable cause for primary amenorrhea. J Pediatr Adolesc Gynecol, 2000. 13(2): p. 93.

38. Endotext.com - Female Reproductive Endocrinology, Ch 4 Bibliography primary ovarian failure a clinicopatholigical and cytogenetic study. Clinical features of primary ovarian failure caused by a point mutation in the http://www.endotext.org/female/female4/femalebiblio4.htm

1. Pettersson F, FriesH, Nillius SJ. Epidemiology of secondary amenrrhea. I. Incidence and prevalent rates. Am J Obstet Gynecol 1973; 117:80-6. 2. Bachman G, Kemmann E. Prevalence of oligmenorrhea and amenorrhea in a college population. Am J Obstet Gynecol 1982; 144:98-102. 3. Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: Implications for evaluation and treatment. Drug and Therapetuics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999; 104:936-41. 4. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990;53:804. 5. Insler V, Melmed H, Mashiah S, Monselise M, Lunenfeld B, Rabau E. Functional classification of patients selected for gonodotropic therapy. Obstet Gynecol 1968; 32:620-626. 6. Block E. Quantitative morphological investigations of the follicular system in women: variations at different ages. Acta Anat 1952; 14:108. 7. Block E. A quantitative morphological investigation of the follicular system in newborn female infants. Acta Anat 1953; 17:201.

39. ICD-10: Block E20-E35 postprocedural ovarian failure ( E89.4 ). E28.0, Estrogen excess. Use additional external cause code E28.3, primary ovarian failure. Decreased estrogen http://www3.who.int/icd/vol1htm2003/ge20.htm

Chapter IV Endocrine, nutritional and metabolic diseases Disorders of other endocrine glands Excludes: galactorrhoea gynaecomastia Hypoparathyroidism Excludes: Di George's syndrome postprocedural hypoparathyroidism tetany NOS transitory neonatal hypoparathyroidism Idiopathic hypoparathyroidism Pseudohypoparathyroidism Other hypoparathyroidism Hypoparathyroidism, unspecified Parathyroid tetany Hyperparathyroidism and other disorders of parathyroid gland Excludes: osteomalacia: Primary hyperparathyroidism Hyperplasia of parathyroid Osteitis fibrosa cystica generalisata [von Recklinghausen's disease of bone] Secondary hyperparathyroidism, not elsewhere classified Excludes: secondary hyperparathyroidism of renal origin Other hyperparathyroidism Excludes: familial hypocalciuric hypercalcaemia Hyperparathyroidism, unspecified Other specified disorders of parathyroid gland Disorder of parathyroid gland, unspecified Hyperfunction of pituitary gland Excludes: Cushing's syndrome Nelson's syndrome overproduction of: Acromegaly and pituitary gigantism Arthropathy associated with acromegaly+ Overproduction of growth hormone Excludes: constitutional: increased secretion from endocrine pancreas of growth hormone-releasing hormone Hyperprolactinaemia Use additional external cause code (Chapter XX), if desired, to identify drug, if drug-induced.

40. Blackwell Synergy - Cookie Absent The development of primary ovarian failure under chemotherapy is caused by Figure 1 shows the incidence of primary ovarian failure, as reflected by the http://www.blackwell-synergy.com/doi/abs/10.1111/j.1600-0609.2005.00459.x

Home An Error Occurred Setting Your User Cookie A cookie is a small amount of information that a web site copies onto your hard drive. Synergy uses cookies to improve performance by remembering that you are logged in when you go from page to page. If the cookie cannot be set correctly, then Synergy cannot determine whether you are logged in and a new session will be created for each page you visit. This slows the system down. Therefore, you must accept the Synergy cookie to use the system. What Gets Stored in a Cookie? Synergy only stores a session ID in the cookie, no other information is captured. In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a web site to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it. Please read our for more information about data collected on this site.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 2     21-40 of 90    Back | 1  | 2  | 3  | 4  | 5  | Next 20